Human Trials Possible launch This Month Owned by Moderna Therapeutics.
Biotech firm launch by Moderna Therapeutics would become the first global company to enter Phase III of a clinical trial for a potential Coronavirus vaccine Dr. Noubar Afeyan, co-founder and chairman of Moderna Therapeutics said
Moderna Therapeutics is owned by U.S company and one of the top contenders in the global race to develop a vaccine to contain the spread of the novel coronavirus or COVID-19
Moderna’s vaccine was among the first to begin testing in humans, conducted by the National Institutes of Health (NIH) in collaboration with the National Institute of Allergy and Infectious Diseases.
There are at least 25 vaccines globally that have advanced to human studies and another 141 that are being tested in a laboratory and still ongoing experiment, according to the World Health Organization. (WHO)
Several Countries work 24/7 to identify the most vulnerable and efficient vaccine that can use and 100% safely on human body to contain the spread of this virus.
“The authorization of Moderna’s vaccine by the Food and Drug Administration will depend on how quickly some 150 cases of the infection occur”,Dr. Noubar Afeyan co-founder and chairman of Moderna Therapeutics said
“The plan is to start enrolling this morning, and this will continue over the next couple of months, We have a very strong demand of folks who volunteered to participate this trial vaccine. Dr. Noubar Afeyan, co-founder and chairman of Moderna Therapeutics said
The blind trial is expected to include 30,000 volunteers. Half of the volunteers will receive Moderna’s Therapeutics Vaccine and the other half will receive a Placebo of Sodium and Water. People 18 years of age and older who are interested in participating in a trial can visit the Coronavirus Prevention Network or ClinicalTrials.gov, with a search identifier NCT04470427 for specific locations Dr. Noubar Afeyan said
“The trial will essentially reach its goals once we hit 150 cases of infection needed to occur statistically to be able to compare the placebo and declare whether the vaccine” provides adequate protection. according to Dr. Noubar Afeyan
I think it’s very important that a person steps up and tries to do something good for the world at this point on the biggest crisis facing the world in many, many centuries.” According to Dr. Noubar Afeyan
It is up to the Food and Drug Administration (FDA) to ensure that all the safety and efficacy measures have been met before the vaccine can be broadly distributed. The FDA has mandated a protection value of at least 50% for any vaccine to be considered for authorization.
Moderna Therapeutics hopes to have authorization by the FDA by the end of 2020. By 2021, Afeyan says the company expects to have between 500 million and 1 billion doses ready for distribution globally upon FDA authorization.
“We and other companies have said that the pandemic is not a time where we intend to use kind of the price as a way to do anything but increase supply so we will certainly be in the market at a price level that allows us to ramp up our supplies and reach potentially up to a billion people next year,” According to Dr. Noubar Afeyan
See Related Post.